4.8 Review

Crohn's disease complicated by strictures: a systematic review

Journal

GUT
Volume 62, Issue 7, Pages 1072-1084

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/gutjnl-2012-304353

Keywords

-

Funding

  1. National Institutes of Health [R01 DK073992, 1T32DK083251- 01A1]
  2. GA Generic Assays GmbH, Germany
  3. UCB Pharmaceuticals
  4. Abbott Laboratories
  5. Abbott
  6. ActoGeniX NV
  7. AGI Therapeutics Inc
  8. Alba Therapeutics Corp
  9. Albireo
  10. Alfa Wasserman
  11. Amgen
  12. AM-Pharma BV
  13. Anaphore
  14. Astellas
  15. Athersys Inc
  16. Atlantic Healthcare Ltd
  17. Aptalis
  18. BioBalance Corp
  19. Boehringer-Ingelheim
  20. Bristol-Myers Squibb
  21. Celgene
  22. Celek Pharmaceuticals
  23. Cellerix SL
  24. Cerimon Pharmaceuticals
  25. ChemoCentryx
  26. CoMentis
  27. Cosmo Technologies
  28. Coronado Biosciences
  29. Cytokine Pharmasciences
  30. Eagle Pharmaceuticals
  31. EnGene Inc
  32. Eli Lilly
  33. Enteromedics
  34. Exagen Diagnostics Inc
  35. Ferring Pharmaceuticals
  36. Flexio Therapeutics Inc
  37. Funxional Therapeutics Ltd
  38. Genzyme Corp
  39. Gilead Sciences
  40. Given Imaging
  41. GlaxoSmithKline
  42. Human Genome Sciences
  43. Ironwood Pharmaceuticals
  44. KaloBios Pharmaceuticals
  45. Lexicon Pharmaceuticals
  46. Lycera Corp
  47. Meda Pharmaceuticals
  48. Merck Research Laboratories
  49. Merck Serono
  50. Millennium Pharmaceuticals
  51. Nisshin Kyorin Pharmaceuticals
  52. Novo Nordisk
  53. NPS Pharmaceuticals
  54. Optimer Pharmaceuticals
  55. Orexigen Therapeutics Inc
  56. PDL Biopharma
  57. Pfizer
  58. Procter and Gamble
  59. Prometheus Laboratories
  60. ProtAb Ltd
  61. Purgenesis Technologies Inc
  62. Relypsa Inc
  63. Roche
  64. Salient Pharmaceuticals
  65. Salix Pharmaceuticals
  66. Santarus
  67. Schering Plough
  68. Shire Pharmaceuticals
  69. Sigmoid Pharma Ltd
  70. Sirtris Pharmaceuticals
  71. SLA Pharma UK Ltd
  72. Targacept
  73. Teva Pharmaceuticals
  74. Therakos
  75. Tilliotts Pharma AG
  76. TxCell SA
  77. UCB Pharma
  78. Viamet Pharmaceuticals
  79. Vascular Biogenics Ltd
  80. Warner Chilcott UK Ltd
  81. Wyeth
  82. Genentech
  83. Janssen
  84. Novartis

Ask authors/readers for more resources

The occurrence of strictures as a complication of Crohn's disease is a significant clinical problem. No specific antifibrotic therapies are available. This systematic review comprehensively addresses the pathogenesis, epidemiology, prediction, diagnosis and therapy of this disease complication. We also provide specific recommendations for clinical practice and summarise areas that require future investigation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available